Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2008

01-10-2008 | Bone and Soft Tissue Sarcomas

Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity

Authors: Marc D. Moncrieff, MD, Hidde M. Kroon, MD, Peter C. Kam, MD, Paul D. Stalley, MB, BS, Richard A. Scolyer, MD, John F. Thompson, MD

Published in: Annals of Surgical Oncology | Issue 10/2008

Login to get access

Abstract

Background

Isolated limb infusion (ILI) is a minimally invasive technique for delivering high-dose regional chemotherapy. We report our experience with ILI for the treatment of soft tissue sarcoma (STS).

Methods

From our prospective database, 21 patients with STS of the limb treated with ILI between 1994 and 2007 were identified. In all patients, a high-dose cytotoxic drug combination was used.

Results

There were 14 men, and the median age was 60 years (range, 18–85 years). Eighteen patients (86%) had lower limb tumors. All patients had advanced local disease. The procedure was well tolerated. Fourteen patients (67%) received ILI before definitive surgery. The overall response rate was 90% (complete response [CR] rate 57%, partial response rate 33%). The disease-specific overall survival was 61.9% (median follow-up, 28 months). Only American Joint Committee on Cancer stage was associated with overall survival. The local recurrence rate was 42%. CR and malignant fibrous histiocytoma tumor subtype were associated with a lower local recurrence rate. A lower initial skin temperature (median 35.8°C) was associated with a CR (P = .033). Patients who had a steep increase in intramuscular temperature during the procedure were more likely to have a CR (P = .055). Classification tree analysis identified patients with an initial PaO2 of ≥194 mmHg as being more likely to have a CR. Ultimately, the overall limb salvage rate was 76%.

Conclusion

The outcomes after ILI are comparable to those achieved by conventional isolated limb perfusion. ILI is a minimally invasive alternative to isolated limb perfusion for patients with advanced STS of the extremity.
Literature
1.
2.
Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol 2002; 9:535–42PubMedCrossRef
3.
Rosenberg SA, Tepper JE, Glatstein EJ, et al. The treatment of soft tissue sarcomas of the extremities: prospective randomised evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196:305–15PubMedCrossRef
4.
Yang JC, Chang AE, Baker AR, et al. A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16:197–203PubMed
5.
O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359:2235–41PubMedCrossRef
6.
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma meta-analysis collaboration. Lancet 1997; 350:1647–54
7.
Schraffordt Koops H, Eggermont AM, Lienard D, et al. Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas. Semin Surg Oncol 1998; 14:210–4PubMedCrossRef
8.
Rooser B, Gustafson P, Rydholm AS. Is there no influence of local control on the rate of metastases in high grade soft tissue sarcoma? Cancer 1990; 65:1727–9PubMedCrossRef
9.
Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994; 7:188–92
10.
Thompson JF, Kam PC, Waugh RC, et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14:238–47PubMedCrossRef
11.
Lindnér P, Doubrovsky A, Kam PCA, et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9:127–36PubMed
12.
Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008 May 29 [Epub ahead of print]
13.
Hegazy MA, Kotb SZ, Sakr H, et al. Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007; 14:568–76PubMedCrossRef
14.
Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004; 1(88):1–3CrossRef
15.
Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905–10PubMedCrossRef
16.
World Health Organization. WHO Handbook for Reporting Results of Cancer Treatments, WHO Offset Publication No. 48. Geneva: World Health Organization, 1979
17.
Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947; 18:50–60CrossRef
18.
Kaplan L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985; 53:457–81CrossRef
19.
Cox DR. Regression models and life table. J Stat Soc 1972; 34:187–220
20.
Kass GV. An exploratory technique for investigating large quantities of categorical data. J Appl Stat 1980; 29:119–27CrossRef
21.
Roberts MS, Wu ZY, Siebert GA, et al. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001; 11:423–31PubMedCrossRef
22.
Parsons PG, Carter FB, Morrison L, et al. Mechanism of melphalan resistance development in human melanoma cells. Cancer Res 1981; 41:1525–34PubMed
23.
Nijhuis PH, Pras E, Sleijfer DT, et al. Long term results of preoperative intra-arterial doxorubicin combined with neoadjuvant radiotherapy followed by extensive surgical resection for locally advanced soft tissue sarcomas of the extremities. Radiother Oncol 1999; 51:15–9PubMedCrossRef
24.
Bezwada HP, Granick MS, Long CD, et al. Soft tissue complications of intra-arterial chemotherapy for extremity sarcoma. Ann Plast Surg 1998; 40:382–7PubMedCrossRef
25.
Soulen MC, Weismann JR, Sullivan KL, et al. Intra-arterial chemotherapy with limb sparing resection of large soft tissue sarcomas of the extremities. J Vasc Interv Radiol 1992; 3:659–63PubMedCrossRef
26.
Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion with TNF-α and melphalan for unresectable soft tissue sarcoma of the extremities. Ann Surg Oncol 2003; 10:S36
27.
Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNF alpha and melphalan for non-resectable soft tissue sarcomas of the extremities. Eur J Surg Oncol 2000; 26:669–78PubMedCrossRef
28.
Rossi CR, Mocellin S, Pilati P, et al. TNF alpha based isolated perfusion for limb threatening soft tissue sarcomas: state of the art and future trends. J Immunother 2003; 26:291–300PubMedCrossRef
29.
Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996; 83:1319–28PubMedCrossRef
30.
Kroon BB. Regional isolation perfusion in melanoma of the limbs: accomplishments, unsolved problems, future. Eur J Surg Oncol 1988; 14:101–10PubMed
31.
Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991; 20:287–9PubMed
32.
Fletcher C, Unni K, Mertens F, eds. So-called fibrohistiocytic tumors. In: World Health Organization. WHO Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon: IARC Press, 2002:120–2
33.
Sanki A, Kam P, Thompson J. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007; 245:591–6PubMedCrossRef
Metadata
Title
Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity
Authors
Marc D. Moncrieff, MD
Hidde M. Kroon, MD
Peter C. Kam, MD
Paul D. Stalley, MB, BS
Richard A. Scolyer, MD
John F. Thompson, MD
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0045-5

Other articles of this Issue 10/2008

Annals of Surgical Oncology 10/2008 Go to the issue

Gynecologic Oncology

Changes in Pulse Oximetry After Patent Blue Dye Injection Into the Uterine Cervix

Gastrointestinal Oncology

Lymphatic Mapping and Sentinel Node Biopsy in the Colonic Mesentery by Natural Orifice Transluminal Endoscopic Surgery (NOTES)

Hepatic and Pancreatic Tumors

Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma

Melanomas

Keystone Flap Reconstruction of Primary Melanoma Excision Defects of the Leg—The End of the Skin Graft?

Hepatic and Pancreatic Tumors

Surgical Management of Hepatocellular Adenoma: Take It or Leave It?

Bone and Soft Tissue Sarcomas

A Large-Scale Study of MT1–MMP as a Marker for Isolated Tumor Cells in Peripheral Blood and Bone Marrow in Gastric Cancer Cases